2. Search Result
Search Result
Results for "

impairment

" in MedChemExpress (MCE) Product Catalog:

354

Inhibitors & Agonists

5

Screening Libraries

4

Biochemical Assay Reagents

21

Peptides

3

Inhibitory Antibodies

72

Natural
Products

7

Isotope-Labeled Compounds

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151518
    Aminopeptidase-IN-1

    		Aminopeptidase Neurological Disease
    Aminopeptidase-IN-1 (compound 16o) is a potent insulin-regulated aminopeptidase (IRAP) inhibitor with an Ki value of 7.7 μM. Aminopeptidase-IN-1 can be used tor research cognitive and memory impairments .
    Aminopeptidase-IN-1
  • HY-N2195
    Nootkatone
    2 Publications Verification

    (+)-Nootkatone

    		 Others Neurological Disease
    Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects . Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease .
    Nootkatone
  • HY-N7981
    Pratensein

    		NF-κB Neurological Disease
    Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .
    Pratensein
  • HY-P2497
    Exendin (5-39)
    1 Publications Verification

    		 GCGR Neurological Disease
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .
    Exendin (5-39)
  • HY-142066
    4′-Demethylnobiletin

    		PKA ERK iGluR Neurological Disease
    4′-Demethylnobiletin is a bioactive metabolite that activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling .
    4′-Demethylnobiletin
  • HY-113069
    Decanoylcarnitine

    		Endogenous Metabolite Metabolic Disease
    Decanoylcarnitine is a fatty ester lipid and an acylcarnitine derivative, which is a metabolite associated with impaired fatty acid metabolism in the elderly population .
    Decanoylcarnitine
  • HY-161909
    USP30-I-1

    		Deubiquitinase Cardiovascular Disease Neurological Disease
    USP30-I-1 is a selective inhibitor of USP30 with an IC50 value of 94 nM. USP30-I-1 can be used in the research of diseases with impaired mitophagy by targeting USP30 .
    USP30-I-1
  • HY-103405
    NGD94-1

    		Dopamine Receptor Neurological Disease
    NGD94-1 is a specific dopamine D4 receptor antagonist. NGD94-1 can effectively reverse Phencyclidine-induced cognitive impairment in marmosets. NGD94-1 can be used in the study of psychiatric diseases .
    NGD94-1
  • HY-114586
    L-158809

    		Angiotensin Receptor Cancer
    L-158809 is an angiotensin type 1 (AT1) receptor antagonist that prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. L-158809 is promising for research of brain tumor .
    L-158809
  • HY-151386
    BChE-IN-13

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-13 (Compound 17c) is an orally active, potent and selective Butyrylcholinesterase (BChE) inhibitor with IC50s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .
    BChE-IN-13
  • HY-132849
    Nezulcitinib

    TD-0903

    		 JAK Infection Inflammation/Immunology
    Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .
    Nezulcitinib
  • HY-121035
    7BIO

    7-Bromoindirubin-3-Oxime

    		 CDK GSK-3 Neurological Disease
    7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
    7BIO
  • HY-131587
    Integerrimine N-oxide

    		Others Others
    Integerrimine N-oxide, the main pyrrolizidine alkaloid found in the butanolic residue (BR) of Senecio brasiliensis. Prenatal exposure to integerrimine N-oxide induces maternal toxicity, impairment of maternal care and delays in physical and behavioral development of the offspring .
    Integerrimine N-oxide
  • HY-W324220
    11β-HSD1-IN-10

    		11β-HSD Metabolic Disease
    11β-HSD1-IN-10 (compound c3a) is a potent 11β-HSD1 inhibitor (IC50=1.8 µM for human). 11β-HSD1-IN-10 can be used in studies of obesity, hyperglycemia and cognitive impairment .
    11β-HSD1-IN-10
  • HY-149473
    AChE-IN-39

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-39 (Compound 7c) is an AChE inhibitor (IC50: 0.058 μM). AChE-IN-39 has DPPH scavenging activity. AChE-IN-39 improves the cognitive impairment in AlCl3-induced amnesia animal model. AChE-IN-39 can be used for research of Alzheimer's disease .
    AChE-IN-39
  • HY-19668A
    SGS518 oxalate

    		5-HT Receptor Neurological Disease
    SGS518 oxalate is a selective 5-HT6R antagonist. SGS518 oxalate can be used for the research of cognitive impairments such as amnesia, anxiety and depression, and it is effective in protecting mouse retina at high doses [1]
    SGS518 oxalate
  • HY-113745
    LX-6171

    		Others Neurological Disease
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia .
    LX-6171
  • HY-163320
    AChE/Aβ-IN-5

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .
    AChE/Aβ-IN-5
  • HY-149318
    VRT-534

    		Others Others
    VRT-534 targets connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50 value of 19 μM and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment .
    VRT-534
  • HY-145831
    sEH/AChE-IN-1

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD) .
    sEH/AChE-IN-1
  • HY-145832
    sEH/AChE-IN-2

    		Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .
    sEH/AChE-IN-2
  • HY-W021358
    N,N,N′,N′-Tetramethyl-p-phenylenediamine

    		Others Metabolic Disease
    N,N,N′,N′-Tetramethyl-p-phenylenediamine (TMPD) is an redox indicator. N,N,N′,N′-Tetramethyl-p-phenylenediamine can be used for the research of impairment of cell respiration .
    N,N,N′,N′-Tetramethyl-p-phenylenediamine
  • HY-111053
    P11

    		Others Cancer
    P11 is a selective inhibitor of platelet-activating factor acetylhydrolases (PAFAHs) 1b2 and 1b3 that impairs cancer cell survival. P11 exhibits IC50 values of ~40 and 900 nM for PAFAH1b2 and 1b3, respectively .
    P11
  • HY-W062702
    BMS-933043

    		nAChR Neurological Disease
    BMS-933043 is a potent and selective α7 nACh receptor partial agonist. BMS-933043 attenuates the cognitive impairment in mice and can be utilized in research related to cognitive dysfunction in schizophrenia .
    BMS-933043
  • HY-138257
    (S)-Indeloxazine benzenesulfonate

    (S)-AS1069562; (S)-YM-08054 benzenesulfonate

    		 Others Neurological Disease
    (S)-AS1069562 is the S-enantiomer of AS1069562 (HY-138257A). AS1069562 is an orally active 5-HT and NE reuptake inhibitor, with IC50 values of 0.35 μM and 3.3 μM, respectively. AS1069562 possesses curative-like analgesic effect. AS1069562 might improve nerve function impairment via the amelioration of neurotrophic support .
    (S)-Indeloxazine benzenesulfonate
  • HY-155593
    JNK-1-IN-2

    		JNK Inflammation/Immunology
    JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC50s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis .
    JNK-1-IN-2
  • HY-W014941
    (R)-(-)-α-Methylhistamine dihydrochloride

    		Histamine Receptor Neurological Disease
    (R)-(-)-α-Methylhistamine dihydrochloride is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM . (R)-(-)-α-Methylhistamine dihydrochloride can enhance memory retention, attenuates memory impairment in rats .
    (R)-(-)-α-Methylhistamine dihydrochloride
  • HY-100999
    (R)-(-)-α-Methylhistamine dihydrobromide

    		Histamine Receptor Neurological Disease
    (R)-(-)-α-Methylhistamine dihydrobromide is a potent, selective and brain-penetrant agonist of H3 histamine receptor, with a Kd of 50.3 nM . (R)-(-)-α-Methylhistamine dihydrobromide can enhance memory retention, attenuates memory impairment in rats .
    (R)-(-)-α-Methylhistamine dihydrobromide
  • HY-W324243
    11β-HSD1-IN-9

    		11β-HSD Metabolic Disease
    11β-HSD1-IN-9 (compound c4a) is a potent 11β-HSD1 inhibitor with IC50 values of 0.48 and 1.3 µM for human and murine 11β-HSD1, respectively. 11β-HSD1-IN-9 competitively interacts with rat 11β-HSD1. 11β-HSD1-IN-19 can be used in studies of obesity, hyperglycemia and cognitive impairment .
    11β-HSD1-IN-9
  • HY-139973
    OAB-14

    		Amyloid-β Neurological Disease
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
    OAB-14
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-N1876
    Aromadendrane-4β,10α-diol

    		Others Neurological Disease
    Aromadendrane-4β,10α-diol is a sesquiterpene alcohol. Aromadendrane-4β,10α-diol significantly ameliorates the Aβ1-42 peptide-induced memory impairment. Aromadendrane-4β,10α-diol can be used for Alzheimer's disease (AD) research .
    Aromadendrane-4β,10α-diol
  • HY-156017
    5-HT6R antagonist 1

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research .
    5-HT6R antagonist 1
  • HY-136092
    Androsta-1,4,6-triene-3,17-dione

    		Cytochrome P450 Neurological Disease Endocrinology
    Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific aromatase inhibitor with a Ki of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory .
    Androsta-1,4,6-triene-3,17-dione
  • HY-100206
    5α-Androstane-3β,5,6β-triol

    		AMPK Neurological Disease
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .
    5α-Androstane-3β,5,6β-triol
  • HY-117985
    Evogliptin

    DA-1229

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin
  • HY-117985B
    Evogliptin tartrate

    DA-1229 tartrate

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin tartrate
  • HY-119358
    Traumatic Acid
    2 Publications Verification

    		 Reactive Oxygen Species Apoptosis Inflammation/Immunology
    Traumatic Acid is a wound healing agent and a cytokinin (phytohormone). Traumatic Acid enhances the biosynthesis of collagen in cultured human skin fibroblasts. Traumatic Acid inhibits MCF-7 breast cancer cells viability and enhances apoptosis and oxidative stress. Traumatic Acid can be used in studies of cancer, circulatory disorders (including arterial hypertension), and skin diseases associated with oxidative stress and impaired collagen biosynthesis .
    Traumatic Acid
  • HY-103157
    PD146176
    4 Publications Verification

    NSC168807

    		 Autophagy Ferroptosis Cardiovascular Disease
    PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
    PD146176
  • HY-151389
    BChE-IN-14

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-14 (compound 19c) is a selective butyrylcholinesterase (BChE) inhibitor with IC50s of 0.23 and 0.011 μM for eqBChE and hBChE, respectively. BChE-IN-14 shows good blood brain barrier permeation and primary cell safety. BChE-IN-14 is able to restore cognitive impairment in vivo, it can be used for the research of Alzheimer’s disease .
    BChE-IN-14
  • HY-118642
    D-Ribose-L-cysteine

    		Cholinesterase (ChE) Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    D-Ribose-L-cysteine ​​is an orally active cysteine ​​analog. D-Ribose-L-cysteine ​​improves cellular antioxidant capacity by enhancing intracellular glutathione (GSH) biosynthesis. In addition, D-Ribose-L-cysteine ​​has a memory-enhancing effect and can reverse Scopolamine (HY-N0296)-induced memory impairment by inhibiting oxidative stress and acetylcholinesterase (AChE) activity. D-Ribose-L-cysteine ​​can be used in the study of neurodegenerative and cardiovascular diseases .
    D-Ribose-L-cysteine
  • HY-146351
    HDAC-IN-38

    		HDAC Neurological Disease
    HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .
    HDAC-IN-38
  • HY-N0293
    Paeoniflorin
    15+ Cited Publications

    Peoniflorin

    		 HSP Infection Neurological Disease Cancer
    Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
    Paeoniflorin
  • HY-N0784
    Ginkgolide B
    4 Publications Verification

    BN-52021

    		 Platelet-activating Factor Receptor (PAFR) Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments .
    Ginkgolide B
  • HY-N0293R
    Paeoniflorin (Standard)

    		HSP Infection Neurological Disease Cancer
    Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
    Paeoniflorin (Standard)
  • HY-N3315
    Massonianoside B

    		Others Inflammation/Immunology
    Massonianoside B is an antioxidant, which can be isolated from Cedrus deodara pine needle. Massonianoside B exhibits radicals scavenging capacities, and restores CCL4-impaired activity of antioxidant enzymes .
    Massonianoside B
  • HY-16361A
    Omigapil maleate

    CGP3466B; CGP3446 maleate; TCH346 maleate

    		 Apoptosis Neurological Disease Metabolic Disease
    Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease . Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD) . Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Omigapil maleate
  • HY-117936
    Muscarinic agonist 1

    		Others Neurological Disease
    Muscarinic agonist 1, AF267, functions by alleviating cognitive impairments.
    Muscarinic agonist 1
  • HY-21972
    BCI-121
    4 Publications Verification

    		 Histone Methyltransferase Cancer
    BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell.
    BCI-121
  • HY-156634
    Risevistinel

    NYX-783

    		 iGluR Neurological Disease
    Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
    Risevistinel

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: